Matthew Taylor, M.D.

Matthew Taylor

Assistant member, Developmental Cancer Therapeutics Laboratory,
Earle A. Chiles Research Institute

Co-director, Providence Melanoma Program,
Providence Cancer Institute

Dr. Taylor is board certified in medical oncology and internal medicine. As a physician scientist, he divides his time between his clinical practice in the Franz Clinic at the Robert W. Franz Cancer Center, and his research laboratory in the Earle A. Chiles Research Institute, a division of Providence Cancer Institute.

His clinical specialties include treating patients with melanoma and advanced thyroid cancer, and conducting early phase clinical trials. An experienced clinical investigator, Dr. Taylor is the national principal investigator on two multicenter clinical trials evaluating the combination of immune checkpoint inhibitors and small molecule inhibitors:

  • Study of the combination of ACP196 and Pembrolizumab in subjects with advanced head and neck squamous cell carcinoma (KEYNOTE 147) NCT02454179.
  • Phase Ib/2 trial of lenvatinib (E7080) plus Pembrolizumab in subjects with selected solid tumors NCT02501096.

In addition to his clinical research, Dr. Taylor studies cancer cells and patients’ tumors in his laboratory. He conducts translational research studies of the mechanisms of immune evasion and biomarkers of therapeutic response to immunotherapy.

Training

Education

  • Fellowship in oncology/hematology, Oregon Health & Science University, Portland, Ore., 2007-2010
  • Residency in internal medicine, University of Washington, Seattle, Wash., 2005-2007
  • Doctor of Medicine, Oregon Health & Science University, Portland, Ore., 2005
  • Bachelor of Science in microbiology/chemistry, Brigham Young University, Provo, Utah, 2001

Professional Experience

  • Associate Member, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Ore., 2019-present
  • Associate Professor, Division of Hematology & Oncology, Oregon Health & Science University, Portland, Ore., 2019-2019
  • Assistant Professor, Division of Hematology & Oncology, Oregon Health & Science University, Portland, Ore., 2010-2019
  • Chief Fellow, Division of Hematology & Oncology, Oregon Health & Science University, Portland, Ore., 2009-2010

Memberships & Awards

Memberships

  • American Association of Cancer Research (AACR)
  • American Society of Clinical Oncology (ASCO)
  • International Thyroid Oncology Group (ITOG)
  • Southwest Oncology Group (SWOG)

Honors & Awards

  • Cum Laude, Oregon Health & Science University Medical School; Portland, Ore., 2003-2005
  • Elizabeth A. Koch Research Award, Finch University of Health Science/The Chicago Medical School, Chicago, Ill., 2002-2003
  • Morris A. Kaplan Research Award, American Academy of Allergy Asthma & Immunology Research Fellowship, 2001-2002
  • Cancer Research Award, Member of the Blue Key National Honor Society, Brigham Young University, Provo, Utah, 2000-2001

Publications

Means C, Clayburgh DR, Maloney L, Sauer D, Taylor MH, Shindo ML, Coussens LM, Tsujikawa T. Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. Head Neck. 2019 Aug;41(8):2636-2646. doi: 10.1002/hed.25740. Epub 2019 Mar 21. PubMed PMID: 30896061.

Duvoisin RM, Ren G, Haley TL, Taylor MH, Morgans CW. TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms. Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2330-2335. doi: 10.1167/iovs.19-26775. PubMed PMID: 31117125.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258. PubMed PMID: 30676622.

Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019 Mar 1;5(3):351-357. doi: 10.1001/jamaoncol.2018.5428. PubMed PMID: 30605211.

Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019 Jan 16;7(1):12. doi: 10.1186/s40425-018-0459-y. PubMed PMID: 30651126.

View Dr. Taylor’s full bibliography.